Description

Quest Diagnostics Unlocks Growth With Corewell Health And Fresenius; But Will It Last?

Quest Diagnostics reported second quarter 2026 results characterized by robust top-line growth and improved profitability driven by increased demand across multiple customer channels, including physicians, hospitals, and consumers. The company generated consolidated revenues of $3.04 billion, reflecting a 10.2% year-over-year increase, with organic revenue growth also at 10%. This growth was fueled by higher volume, particularly from collaborations with Corewell Health and Fresenius Medical Care, which contributed significantly to volume expansion. Total requisitions increased 13.1%, with organic volume up by 13%. Adjusted diluted earnings per share rose by 19.1% to $3.12, driven largely by organic operating improvements and a favorable tax contingency resolution contributing approximately $0.10 per share. Operating margins, however, showed a slight decline on a reported basis to 16.5% of revenues compared to 16.